Immunology:
Our other therapy areas

    • {%buzitemName%}
        {%buzbrandMenuItems%}
    • {%bitemName%} {%barrowSpan%}
        {%bsubBrandMenuItems%}
    • {%sbitemName%} {%sbarrowSpan%}
        {%sbproductMenuItems%}
    • {%pitemKeyName%} {%pitemBadges%} {%parrowSpan%}
      {%pselfProduct%}
    • {%mNavitemName%}
      • {%lScountries%}
    • {%allMenuItem%}
      • {%cSlanguages%}

      • This website is intended for Healthcare Professionals working in Ireland

      Skyrizi_Logo_GLOBAL-R-640

       

       

      PRESCRIBING INFORMATION
      Contact Us
      RESOURCES AND EVENTS
      SmPC 180mg
      SmPC 360mg
      SmPC 600mg

      Skyrizi is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response to, lost response to, or were intolerant to conventional therapy or a biologic therapy.1

       

      Take Back Control
      lab-v2

      CLINICAL PROFILE

      Find out more
      teae

      RESOURCES AND EVENTS

      Find out more
      icon-check-v1

      SAFETY PROFILE

      Find out more
      icon-induction-v1

      INITIATION AND DOSING

      Find out more

      References:

      1. SKYRIZI Summary of Product Characteristics (SmPC) available at www.medicines.ie. 

      2. AbbVie defines control as endoscopic response and clinical remission. Endoscopic response: greater than 50% decrease in SES-CD from baseline, or a decrease of at    least 2 points for subjects with a baseline score of 4 and isolated ileal disease.2 Clinical remission (SF/APS): average daily SF ≤2.8 and not worse than baseline and average daily APS ≤1 and not worse than baseline.

       

      SKYRIZI PRESCRIBING INFORMATION

       

      IE-SKZG-250046​ | Date of preparation: January 2026

      Our therapy areas
      Haematology
      Neurology
      Immunology
      Additional info
      Privacy Policy
      Terms and Conditions

       

      Reporting an Adverse Event: Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via Health Products Regulatory Authority (HPRA) Pharmacovigilance. www.hpra.ie.

       

      This website is intended for Healthcare Professionals working in Ireland
      Copyright© 2026 AbbVie Inc.

      Unless otherwise specified, all product names appearing in this internet site are trademarks owned or licensed by AbbVie Inc., its subsidiaries or affiliates. No use of any AbbVie trademark, trade names or trade dress in this site may be made without the prior written authorisation of AbbVie Inc., except to identify the product or services of the company

      AbbVie Pro is developed and funded by AbbVie Limited

      AbbVie Limited, a private company limited by Shares, and a member of the AbbVie group of companies.

      Registered in Ireland with Company Number 510846.

      Local contact details: 14 Riverwalk, Citywest Business Campus, Dublin 24, D24 XN32, Ireland.
      Tel (0) 1 4287900. www.abbvie.ie

      Date of Preparation: October 2025 | IE-ABBV-220078